1,055 results on '"Toffoli, Giuseppe"'
Search Results
2. Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
3. Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method
4. A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma
5. The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity
6. Surface antibody changes protein corona both in human and mouse serum but not final opsonization and elimination of targeted polymeric nanoparticles
7. Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
8. Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study
9. Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer
10. Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure
11. A fast and validated LC-MS/MS method to quantify lenvatinib in dried blood spot
12. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
13. Targeted therapy for multiple myeloma: an overview on CD138-based strategies
14. Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
15. Bioanalytical Methods for Poly(ADP-Ribose) Polymerase Inhibitor Quantification: A Review for Therapeutic Drug Monitoring
16. “A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring”
17. Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients
18. Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and Opportunities.
19. A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer
20. Machine learning in onco-pharmacogenomics: a path to precision medicine with many challenges
21. Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
22. Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
23. Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19
24. Dried Blood Spot Technique Applied in Therapeutic Drug Monitoring of Anticancer Drugs: a Review on Conversion Methods to Correlate Plasma and Dried Blood Spot Concentrations
25. Development and validation of a selective SPR aptasensor for the detection of anticancer drug irinotecan in human plasma samples
26. A LC–MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma
27. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma
28. A new high-performance liquid chromatography–tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine
29. A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer
30. Oral Administration of Cancer Vaccines: Challenges and Future Perspectives
31. Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?
32. Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation
33. A fast method for the detection of irinotecan in plasma samples by combining solid phase extraction and differential pulse voltammetry
34. A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study
35. Voltammetric behaviour of the anticancer drug irinotecan and its metabolites in acetonitrile. Implications for electrochemical therapeutic drug monitoring
36. Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine
37. Oral Administration of Cancer Vaccines: Challenges and Future Perspectives.
38. A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
39. 243 Anti-GPC1 IgM activating the complement system is an effective treatment in a pancreatic ductal adenocarcinoma mouse model
40. Anti‐HER2 Super Stealth Immunoliposomes for Targeted‐Chemotherapy
41. Machine learning to improve interpretability of clinical, radiological and panel-based genomic data of glioma grade 4 patients undergoing surgical resection
42. Practical fluorimetric assay for the detection of anticancer drug SN-38 in human plasma
43. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation
44. Peptide biosensors for anticancer drugs: Design in silico to work in denaturizing environment
45. Pre-treatment molecular profiling identifies predictive and prognostic fingerprints in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: implications for treatment selection
46. Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models
47. Machine Learning Application Identifies Germline Markers of Hypertension in Ovarian Cancer Patients Treated with Carboplatin, Taxane and Bevacizumab
48. LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
49. Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia
50. Bottom-up synthesis of carbon nanoparticles with higher doxorubicin efficacy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.